REFERENCES
1. Chen Z, Zhang P, Xu Y, et al. Surgical stress and cancer progression: the twisted tango. Mol Cancer. 2019;18:132.
2. Grewal AS, Jones J, Lin A. Palliative radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2019;105:254-66.
3. Ippolito MR, Martis V, Martin S, et al. Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. Dev Cell. 2021;56:2440-54.e6.
4. Tímár J, Uhlyarik A. On-target side effects of targeted therapeutics of cancer. Pathol Oncol Res. 2022;28:1610694.
5. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807-21.
6. Zeng D, Wu J, Luo H, et al. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J Immunother Cancer. 2021;9:e002467.
7. Huang H, Nie CP, Liu XF, et al. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer. J Clin Invest. 2022;132:e157726.
8. Mailankody S, Devlin SM, Landa J, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196-206.
9. Walle T, Kraske JA, Liao B, et al. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci Adv. 2022;8:eabh4050.
10. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10:e005755.
11. Li S, Yu W, Xie F, et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023;14:8.
12. Duan H, Zhang X, Wang FX, et al. KIF-2C expression is correlated with poor prognosis of operable esophageal squamous cell carcinoma male patients. Oncotarget. 2016;7:80493-507.
13. Cai Y, Mei J, Xiao Z, et al. Identification of five hub genes as monitoring biomarkers for breast cancer metastasis in silico. Hereditas. 2019;156:20.
14. Wang F, Li J, Li L, et al. Circular RNA circ_IRAK3 contributes to tumor growth through upregulating KIF2A via adsorbing miR-603 in breast cancer. Cancer Cell Int. 2022;22:81.
15. Huang J, Sun X, Diao G, Li R, Guo J, Han J. KIF15 knockdown inhibits the development of endometrial cancer by suppressing epithelial-mesenchymal transition and stemness through Wnt/β-catenin signaling. Environ Toxicol. 2023;1824:34.
16. Zeng S, Wang Q, Zhou R, Wang D. KIF4A functions as a diagnostic and prognostic biomarker and regulates tumor immune microenvironment in skin cutaneous melanoma. Pathol Res Pract. 2024;254:155166.
17. Zhong M, Gong L, Li N, et al. Pan-cancer analysis of kinesin family members with potential implications in prognosis and immunological role in human cancer. Front Oncol. 2023;13:1179897.
18. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-4.
19. Liu CJ, Hu FF, Xie GY, et al. GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief Bioinform. 2023;24:bbac558.
20. Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:eaan2507.
21. Thul PJ, Åkesson L, Wiking M, et al. A subcellular map of the human proteome. Science. 2017;356:eaal3321.
22. Sturm G, Finotello F, Petitprez F, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019;35:i436-45.
23. Li X, Tai Y, Liu S, et al. Bioinformatics analysis: relationship between adrenocortical carcinoma and KIFs. Biotechnol Genet Eng Rev. 2023;39:575-85.
24. Xiao KH, Teng K, Ye YL, et al. Kinesin family member C1 accelerates bladder cancer cell proliferation and induces epithelial-mesenchymal transition via Akt/GSK3β signaling. Cancer Sci. 2019;110:2822-33.
25. Wang J, Wang D, Fei Z, et al. KIF15 knockdown suppresses gallbladder cancer development. Eur J Cell Biol. 2021;100:151182.
26. Hu ZD, Jiang Y, Sun HM, et al. KIF11 promotes proliferation of hepatocellular carcinoma among patients with liver cancers. Biomed Res Int. 2021;2021:2676745.
27. Xie T, Li X, Ye F, et al. High KIF2A expression promotes proliferation, migration and predicts poor prognosis in lung adenocarcinoma. Biochem Biophys Res Commun. 2018;497:65-72.
28. Gu R, Li X, Yan X, Feng Z, Hu A. Circular RNA circ_0032462 enhances osteosarcoma cell progression by promoting KIF3B expression. Technol Cancer Res Treat. 2020;19:1533033820943217.
29. Joseph NF, Grinman E, Swarnkar S, Puthanveettil SV. Molecular motor KIF3B acts as a key regulator of dendritic architecture in cortical neurons. Front Cell Neurosci. 2020;14:521199.
30. Duan Y, Xu X. A signature based on anoikis-related genes for the evaluation of prognosis, immunoinfiltration, mutation, and therapeutic response in ovarian cancer. Front Endocrinol. 2023;14:1193622.
31. Qin H, Lu H, Qin C, et al. Pan-cancer analysis suggests that LY6H is a potential biomarker of diagnosis, immunoinfiltration, and prognosis. J Cancer. 2024;15:5515-39.
32. Guo X, Zhou L, Wu Y, Li J. KIF11 As a potential pan-cancer immunological biomarker encompassing the disease staging, prognoses, tumor microenvironment, and therapeutic responses. Oxid Med Cell Longev. 2022;2022:2764940.
33. Qiu MJ, Wang QS, Li QT, et al. KIF18B is a prognostic biomarker and correlates with immune infiltrates in pan-cancer. Front Mol Biosci. 2021;8:559800.
34. Cao Z, Guan M, Cheng C, et al. KIF20B and MET, hub genes of DIAPHs, predict poor prognosis and promote pancreatic cancer progression. Pathol Res Pract. 2024;254:155046.
35. Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509-14.
36. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423-37.
37. Leong SP, Aktipis A, Maley C. Cancer initiation and progression within the cancer microenvironment. Clin Exp Metastasis. 2018;35:361-7.
38. Li Q, Chen Q, Klauser PC, et al. Developing covalent protein drugs via proximity-enabled reactive therapeutics. Cell. 2020;182:85-97.e16.
39. Spitzer MH, Carmi Y, Reticker-Flynn NE, et al. Systemic immunity is required for effective cancer immunotherapy. Cell. 2017;168:487-502.e15.
